Safety, Tolerability, and Pharmacokinetics of the Long‐Acting SARS‐CoV‐2–Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese Adults

Documenti analoghi

• Safety and Pharmacokinetics of Long‐Acting Monoclonal Antibodies Tixagevimab and Cilgavimab (AZD7442) in a China Phase 2 Study and Evaluation of Asian Race Effect
  di: Jing Zhang, et al.
  Pubblicazione: (2025)
• Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS‐CoV‐2 Variants: A Case Report Study with Comparison to a Vaccinated Population
  di: Constant Gillot, et al.
  Pubblicazione: (2024)
• Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections
  di: Posch, Wilfried
  Pubblicazione: (2022)
• Safety, Tolerability, and Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, in Healthy Chinese Participants
  di: Jingjing Wang, et al.
  Pubblicazione: (2025)
• SARS‐CoV‐2 Vaccination Rates and Uptake of Tixagevimab‐Cilgavimab Among a Cohort of Pediatric Solid Organ Transplant Recipients
  di: Christopher A. Reis, et al.
  Pubblicazione: (2024)